{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T04:55:12Z","timestamp":1766811312495,"version":"3.48.0"},"reference-count":80,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2025]]},"DOI":"10.3960\/jslrt.25041","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T22:06:36Z","timestamp":1761775596000},"page":"238-246","source":"Crossref","is-referenced-by-count":0,"title":["Pathobiological link between CD30 and abnormal lymphocytes in adult T-cell leukemia\/lymphoma"],"prefix":"10.3960","volume":"65","author":[{"given":"Ryouichi","family":"Horie","sequence":"first","affiliation":[{"name":"Department of Medical Therapeutics, Faculty of Health and Medical Sciences, Kanagawa Institute of Technology, Atsugi, Kanagawa, Japan,"},{"name":"Department of Molecular Cell Therapy, Kitasato University Graduate School of Medical Sciences, Sagamihara, Kanagawa, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Blood Transfusion, Kitasato University Hospital, Sagamihara, Kanagawa, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiko","family":"Furuta","sequence":"additional","affiliation":[{"name":"Clinical Cytology, Department of Medical Laboratory Sciences, School of Allied Health Sciences, Kitasato University, Sagamihara, Kanagawa, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Molecular Cell Therapy, Kitasato University Graduate School of Medical Sciences, Sagamihara, Kanagawa, Japan,"},{"name":"Department of Transfusion and Cell Transplantation, School of Medicine, Kitasato University, Sagamihara, Kanagawa, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, St. Marianna University, Kawasaki, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"doi-asserted-by":"crossref","unstructured":"1 Schwab U, Stein H, Gerdes J <i>et al.<\/i> Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin\u2019s disease and a subset of normal lymphoid cells. Nature. 1982; 299: 65-67.","key":"1","DOI":"10.1038\/299065a0"},{"doi-asserted-by":"crossref","unstructured":"2 Stein H, Gerdes J, Schwab U <i>et al.<\/i> Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population. Int J Cancer. 1982; 30: 445-459.","key":"2","DOI":"10.1002\/ijc.2910300411"},{"doi-asserted-by":"crossref","unstructured":"3 D\u00fcrkop H, Latza U, Hummel M <i>et al.<\/i> Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin\u2019s disease. Cell. 1992; 68: 421-427.","key":"3","DOI":"10.1016\/0092-8674(92)90180-K"},{"doi-asserted-by":"crossref","unstructured":"4 Smith CA, Gruss HJ, Davis T <i>et al.<\/i> CD30 antigen, a marker for Hodgkin\u2019s lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell. 1993; 73: 1349-1360.","key":"4","DOI":"10.1016\/0092-8674(93)90361-S"},{"doi-asserted-by":"crossref","unstructured":"5 Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol. 1998; 10: 457-470.","key":"5","DOI":"10.1006\/smim.1998.0156"},{"doi-asserted-by":"crossref","unstructured":"6 Imaizumi Y, Iwanaga M, Nosaka K <i>et al.<\/i> Prognosis of patients with adult T-cell leukemia\/lymphoma in Japan: A nationwide hospital-based study. Cancer Sci. 2020; 111: 4567-4580.","key":"6","DOI":"10.1111\/cas.14658"},{"doi-asserted-by":"crossref","unstructured":"7 Ishida T, Joh T, Uike N <i>et al.<\/i> Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012; 30: 837-842.","key":"7","DOI":"10.1200\/JCO.2011.37.3472"},{"doi-asserted-by":"crossref","unstructured":"8 Izutsu K, Makita S, Nosaka K <i>et al.<\/i> An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia\/lymphoma. Blood. 2023; 141: 1159-1168.","key":"8","DOI":"10.1182\/blood.2022016862"},{"doi-asserted-by":"crossref","unstructured":"9 Utsunomiya A, Izutsu K, Jo T <i>et al.<\/i> Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia\/lymphoma: Phase IIb results. Cancer Sci. 2022; 113: 2778-2787.","key":"9","DOI":"10.1111\/cas.15431"},{"doi-asserted-by":"crossref","unstructured":"10 Makiyama J, Ishitsuka K, Munakata W, Maruyama D, Nagai H. An update on the developments in the treatment of adult T-cell leukemia-lymphoma: current knowledge and future perspective. Jpn J Clin Oncol. 2023; 53: 1104-1111.","key":"10","DOI":"10.1093\/jjco\/hyad108"},{"doi-asserted-by":"crossref","unstructured":"11 Ohtsuka E, Kikuchi H, Nasu M <i>et al.<\/i> Clinicopathological features of adult T-cell leukemia with CD30 antigen expression. Leuk Lymphoma. 1994; 15: 303-310.","key":"11","DOI":"10.3109\/10428199409049728"},{"doi-asserted-by":"crossref","unstructured":"12 Takeshita M, Akamatsu M, Ohshima K <i>et al.<\/i> CD30 (Ki-1) expression in adult T-cell leukaemia\/lymphoma is associated with distinctive immunohistological and clinical characteristics. Histopathology. 1995; 26: 539-546.","key":"12","DOI":"10.1111\/j.1365-2559.1995.tb00272.x"},{"doi-asserted-by":"crossref","unstructured":"13 Karube K, Aoki R, Nomura Y <i>et al.<\/i> Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases. Pathol Int. 2008; 58: 89-97.","key":"13","DOI":"10.1111\/j.1440-1827.2007.02195.x"},{"doi-asserted-by":"crossref","unstructured":"14 Oka S, Ono K, Nohgawa M. Successful treatment with brentuximab vedotin for relapsed and refractory adult T cell leukemia. Anticancer Drugs. 2020; 31: 536-539.","key":"14","DOI":"10.1097\/CAD.0000000000000895"},{"doi-asserted-by":"crossref","unstructured":"15 Baba Y, Sakai H, Kabasawa N, Harada H. Successful Treatment of an Aggressive Adult T-cell Leukemia\/Lymphoma with Strong CD30 Expression Using Brentuximab Vedotin as Combination and Maintenance Therapy. Intern Med. 2023; 62: 613-616.","key":"15","DOI":"10.2169\/internalmedicine.9812-22"},{"doi-asserted-by":"crossref","unstructured":"16 Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977; 50: 481-492.","key":"16","DOI":"10.1182\/blood.V50.3.481.bloodjournal503481"},{"doi-asserted-by":"crossref","unstructured":"17 Ohshima K. Pathological features of diseases associated with human T-cell leukemia virus type I. Cancer Sci. 2007; 98: 772-778.","key":"17","DOI":"10.1111\/j.1349-7006.2007.00456.x"},{"unstructured":"18 Karube K, Takatori M, Sakihama S <i>et al.<\/i> Clinicopathological features of adult T-cell leukemia\/lymphoma with HTLV-1-infected Hodgkin and Reed-Sternberg-like cells. Blood Adv. 2021; 5: 198-206.","key":"18"},{"unstructured":"19 Karube K, Cook LB, Ishitsuka K, <i>et al.<\/i>: Adult T-cell leukaemia\/lymphoma. In: WHO Classification of Tumours Editorial Board (eds): Haematolymphoid Tumours, WHO Classification of Tumours. 5th ed, Lyon, International Agency for Research on Cancer. 2024; pp. 667-673.","key":"19"},{"doi-asserted-by":"crossref","unstructured":"20 Nakashima M, Yamochi T, Watanabe M <i>et al.<\/i> CD30 Characterizes Polylobated Lymphocytes and Disease Progression in HTLV-1-Infected Individuals. Clin Cancer Res. 2018; 24: 5445-5457.","key":"20","DOI":"10.1158\/1078-0432.CCR-18-0268"},{"doi-asserted-by":"crossref","unstructured":"21 Poiesz BJ, Ruscetti FW, Reitz MS, Kalyanaraman VS, Gallo RC. Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with S\u00e9zary T-cell leukaemia. Nature. 1981; 294: 268-271.","key":"21","DOI":"10.1038\/294268a0"},{"doi-asserted-by":"crossref","unstructured":"22 Seiki M, Hattori S, Hirayama Y, Yoshida M. Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. Proc Natl Acad Sci U S A. 1983; 80: 3618-3622.","key":"22","DOI":"10.1073\/pnas.80.12.3618"},{"doi-asserted-by":"crossref","unstructured":"23 Watanabe T, Seiki M, Yoshida M. HTLV type I (U. S. isolate) and ATLV (Japanese isolate) are the same species of human retrovirus. Virology. 1984; 133: 238-241.","key":"23","DOI":"10.1016\/0042-6822(84)90446-X"},{"doi-asserted-by":"crossref","unstructured":"24 Gessain A, Cassar O. Epidemiological Aspects and World Distribution of HTLV-1 Infection. Front Microbiol. 2012; 3: 388.","key":"24","DOI":"10.3389\/fmicb.2012.00388"},{"doi-asserted-by":"crossref","unstructured":"25 Iwanaga M, Watanabe T, Yamaguchi K. Adult T-cell leukemia: a review of epidemiological evidence. Front Microbiol. 2012; 3: 322.","key":"25","DOI":"10.3389\/fmicb.2012.00322"},{"doi-asserted-by":"crossref","unstructured":"26 Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991; 79: 428-437.","key":"26","DOI":"10.1111\/j.1365-2141.1991.tb08051.x"},{"doi-asserted-by":"crossref","unstructured":"27 Mohanty S, Harhaj EW. Mechanisms of Oncogenesis by HTLV-1 Tax. Pathogens. 2020; 9: 543.","key":"27","DOI":"10.3390\/pathogens9070543"},{"doi-asserted-by":"crossref","unstructured":"28 Ma G, Yasunaga J, Matsuoka M. Multifaceted functions and roles of HBZ in HTLV-1 pathogenesis. Retrovirology. 2016; 13: 16.","key":"28","DOI":"10.1186\/s12977-016-0249-x"},{"doi-asserted-by":"crossref","unstructured":"29 Kataoka K, Nagata Y, Kitanaka A <i>et al.<\/i> Integrated molecular analysis of adult T cell leukemia\/lymphoma. Nat Genet. 2015; 47: 1304-1315.","key":"29","DOI":"10.1038\/ng.3415"},{"doi-asserted-by":"crossref","unstructured":"30 Rodriguez J, Pugh W, Romaguera J, Cabanillas F. Anaplastic Ki-1 + large-cell lymphoma. Cancer Invest. 1993; 11: 554-558.","key":"30","DOI":"10.3109\/07357909309011673"},{"doi-asserted-by":"crossref","unstructured":"31 Sabattini E, Pizzi M, Tabanelli V <i>et al.<\/i> CD30 expression in peripheral T-cell lymphomas. Haematologica. 2013; 98: e81-e82.","key":"31","DOI":"10.3324\/haematol.2013.084913"},{"doi-asserted-by":"crossref","unstructured":"32 Malysz J, Erdman P, Klapper J <i>et al.<\/i> Clinical Implications of CD30 Expression in Aggressive B-Cell Lymphomas. Clin Lymphoma Myeloma Leuk. 2016; 16: 429-433.","key":"32","DOI":"10.1016\/j.clml.2016.04.011"},{"doi-asserted-by":"crossref","unstructured":"33 D\u00fcrkop H, Foss HD, Eitelbach F <i>et al.<\/i> Expression of the CD30 antigen in non-lymphoid tissues and cells. J Pathol. 2000; 190: 613-618.","key":"33","DOI":"10.1002\/(SICI)1096-9896(200004)190:5<613::AID-PATH559>3.3.CO;2-S"},{"doi-asserted-by":"crossref","unstructured":"34 Stein H, Mason DY, Gerdes J <i>et al.<\/i> The expression of the Hodgkin\u2019s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985; 66: 848-858.","key":"34","DOI":"10.1182\/blood.V66.4.848.848"},{"unstructured":"35 Ito K, Watanabe T, Horie R <i>et al.<\/i> High expression of the CD30 molecule in human decidual cells. Am J Pathol. 1994; 145: 276-280.","key":"35"},{"unstructured":"36 Gruss HJ, DaSilva N, Hu ZB <i>et al.<\/i> Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines. Leukemia. 1994; 8: 2083-2094.","key":"36"},{"unstructured":"37 Gruss HJ, Pinto A, Gloghini A <i>et al.<\/i> CD30 ligand expression in nonmalignant and Hodgkin\u2019s disease-involved lymphoid tissues. Am J Pathol. 1996; 149: 469-481.","key":"37"},{"doi-asserted-by":"crossref","unstructured":"38 Pinto A, Aldinucci D, Gloghini A <i>et al.<\/i> Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin\u2019s disease cell line. Blood. 1996; 88: 3299-3305.","key":"38","DOI":"10.1182\/blood.V88.9.3299.bloodjournal8893299"},{"doi-asserted-by":"crossref","unstructured":"39 Younes A, Consoli U, Zhao S <i>et al.<\/i> CD30 ligand is expressed on resting normal and malignant human B lymphocytes. Br J Haematol. 1996; 93: 569-571.","key":"39","DOI":"10.1046\/j.1365-2141.1996.d01-1686.x"},{"doi-asserted-by":"crossref","unstructured":"40 Josimovic-Alasevic O, D\u00fcrkop H, Schwarting R <i>et al.<\/i> Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol. 1989; 19: 157-162.","key":"40","DOI":"10.1002\/eji.1830190125"},{"doi-asserted-by":"crossref","unstructured":"41 Hansen HP, Dietrich S, Kisseleva T <i>et al.<\/i> CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-alpha-converting enzyme. J Immunol. 2000; 165: 6703-6709.","key":"41","DOI":"10.4049\/jimmunol.165.12.6703"},{"doi-asserted-by":"crossref","unstructured":"42 Pizzolo G, Vinante F, Chilosi M <i>et al.<\/i> Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin\u2019s disease: relationship with disease activity and clinical stage. Br J Haematol. 1990; 75: 282-284.","key":"42","DOI":"10.1111\/j.1365-2141.1990.tb02664.x"},{"doi-asserted-by":"crossref","unstructured":"43 Gedrich RW, Gilfillan MC, Duckett CS, Van Dongen JL, Thompson CB. CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. J Biol Chem. 1996; 271: 12852-12858.","key":"43","DOI":"10.1074\/jbc.271.22.12852"},{"doi-asserted-by":"crossref","unstructured":"44 Nakashima M, Watanabe M, Uchimaru K, Horie R. Trogocytosis of ligand-receptor complex and its intracellular transport in CD30 signalling. Biol Cell. 2018; 110: 109-124.","key":"44","DOI":"10.1111\/boc.201800002"},{"doi-asserted-by":"crossref","unstructured":"45 Lee SY, Lee SY, Kandala G <i>et al.<\/i> CD30\/TNF receptor-associated factor interaction: NF-kappa B activation and binding specificity. Proc Natl Acad Sci U S A. 1996; 93: 9699-9703.","key":"45","DOI":"10.1073\/pnas.93.18.9699"},{"doi-asserted-by":"crossref","unstructured":"46 Zheng B, Fiumara P, Li YV <i>et al.<\/i> MEK\/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood. 2003; 102: 1019-1027.","key":"46","DOI":"10.1182\/blood-2002-11-3507"},{"doi-asserted-by":"crossref","unstructured":"47 Harlin H, Podack E, Boothby M, Alegre ML. TCR-independent CD30 signaling selectively induces IL-13 production via a TNF receptor-associated factor\/p38 mitogen-activated protein kinase-dependent mechanism. J Immunol. 2002; 169: 2451-2459.","key":"47","DOI":"10.4049\/jimmunol.169.5.2451"},{"doi-asserted-by":"crossref","unstructured":"48 Georgakis GV, Li Y, Rassidakis GZ <i>et al.<\/i> Inhibition of the phosphatidylinositol-3 kinase\/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br J Haematol. 2006; 132: 503-511.","key":"48","DOI":"10.1111\/j.1365-2141.2005.05881.x"},{"doi-asserted-by":"crossref","unstructured":"49 Gruss HJ, Boiani N, Williams DE <i>et al.<\/i> Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood. 1994; 83: 2045-2056.","key":"49","DOI":"10.1182\/blood.V83.8.2045.2045"},{"doi-asserted-by":"crossref","unstructured":"50 Shanebeck KD, Maliszewski CR, Kennedy MK <i>et al.<\/i> Regulation of murine B cell growth and differentiation by CD30 ligand. Eur J Immunol. 1995; 25: 2147-2153.","key":"50","DOI":"10.1002\/eji.1830250805"},{"doi-asserted-by":"crossref","unstructured":"51 Sun X, Yamada H, Shibata K <i>et al.<\/i> CD30 ligand\/CD30 plays a critical role in Th17 differentiation in mice. J Immunol. 2010; 185: 2222-2230.","key":"51","DOI":"10.4049\/jimmunol.1000024"},{"doi-asserted-by":"crossref","unstructured":"52 Takemoto S, Iwanaga M, Sagara Y, Watanabe T. Plasma Soluble CD30 as a Possible Marker of Adult T-cell Leukemia in HTLV-1 Carriers: a Nested Case-Control Study. Asian Pac J Cancer Prev. 2015; 16: 8253-8258.","key":"52","DOI":"10.7314\/APJCP.2015.16.18.8253"},{"doi-asserted-by":"crossref","unstructured":"53 Hanaoka M, Sasaki M, Matsumoto H <i>et al.<\/i> Adult T cell leukemia. Histological classification and characteristics. Acta Pathol Jpn. 1979; 29: 723-738.","key":"53","DOI":"10.1111\/j.1440-1827.1979.tb00940.x"},{"doi-asserted-by":"crossref","unstructured":"54 Ohshima K, Kikuchi M, Yoshida T, Masuda Y, Kimura N. Lymph nodes in incipient adult T-cell leukemia-lymphoma with Hodgkin\u2019s disease-like histologic features. Cancer. 1991; 67: 1622-1628.","key":"54","DOI":"10.1002\/1097-0142(19910315)67:6<1622::AID-CNCR2820670625>3.0.CO;2-1"},{"doi-asserted-by":"crossref","unstructured":"55 Ohshima K, Suzumiya J, Kato A, Tashiro K, Kikuchi M. Clonal HTLV-I-infected CD4+ T-lymphocytes and non-clonal non-HTLV-I-infected giant cells in incipient ATLL with Hodgkin-like histologic features. Int J Cancer. 1997; 72: 592-598.","key":"55","DOI":"10.1002\/(SICI)1097-0215(19970807)72:4<592::AID-IJC7>3.0.CO;2-L"},{"doi-asserted-by":"crossref","unstructured":"56 Nakamura N, Mori N, Ohshima K <i>et al.<\/i> Epstein-Barr virus-positive Hodgkin\/Reed-Sternberg-like B cell in non-hodgkin lymphoma: nucleotide sequence of the amplified immunoglobulin heavy-chain variable region gene by the single-cell polymerase chain reaction technique. Diagn Mol Pathol. 2002; 11: 83-89.","key":"56","DOI":"10.1097\/00019606-200206000-00004"},{"doi-asserted-by":"crossref","unstructured":"57 Watanabe M, Hatsuse H, Nagao K <i>et al.<\/i> CD30 stimulation induces multinucleation and chromosomal instability in HTLV-1-infected cell lines. Int J Hematol. 2023; 118: 75-87.","key":"57","DOI":"10.1007\/s12185-023-03583-1"},{"doi-asserted-by":"crossref","unstructured":"58 Fukuda R, Hayashi A, Utsunomiya A <i>et al.<\/i> Alteration of phosphatidylinositol 3-kinase cascade in the multilobulated nuclear formation of adult T cell leukemia\/lymphoma (ATLL). Proc Natl Acad Sci U S A. 2005; 102: 15213-15218.","key":"58","DOI":"10.1073\/pnas.0507184102"},{"doi-asserted-by":"crossref","unstructured":"59 Chandel NS, Schumacker PT, Arch RH. Reactive oxygen species are downstream products of TRAF-mediated signal transduction. J Biol Chem. 2001; 276: 42728-42736.","key":"59","DOI":"10.1074\/jbc.M103074200"},{"doi-asserted-by":"crossref","unstructured":"60 Ganem NJ, Pellman D. Linking abnormal mitosis to the acquisition of DNA damage. J Cell Biol. 2012; 199: 871-881.","key":"60","DOI":"10.1083\/jcb.201210040"},{"doi-asserted-by":"crossref","unstructured":"61 Pampalona J, Fr\u00edas C, Genesc\u00e0 A, Tusell L. Progressive telomere dysfunction causes cytokinesis failure and leads to the accumulation of polyploid cells. PLoS Genet. 2012; 8: e1002679.","key":"61","DOI":"10.1371\/journal.pgen.1002679"},{"doi-asserted-by":"crossref","unstructured":"62 Nakashima M, Utsunomiya A, Watanabe T, Horie R, Uchimaru K. The oncogenic driving force of CD30 signaling-induced chromosomal instability in adult T-cell leukemia\/lymphoma. Cancer Sci. 2023; 114: 1556-1568.","key":"62","DOI":"10.1111\/cas.15706"},{"doi-asserted-by":"crossref","unstructured":"63 Mills KD, Ferguson DO, Alt FW. The role of DNA breaks in genomic instability and tumorigenesis. Immunol Rev. 2003; 194: 77-95.","key":"63","DOI":"10.1034\/j.1600-065X.2003.00060.x"},{"doi-asserted-by":"crossref","unstructured":"64 Sansregret L, Swanton C. The Role of Aneuploidy in Cancer Evolution. Cold Spring Harb Perspect Med. 2017; 7: a028373.","key":"64","DOI":"10.1101\/cshperspect.a028373"},{"doi-asserted-by":"crossref","unstructured":"65 Shoshani O, Bakker B, de Haan L <i>et al.<\/i> Transient genomic instability drives tumorigenesis through accelerated clonal evolution. Genes Dev. 2021; 35: 1093-1108.","key":"65","DOI":"10.1101\/gad.348319.121"},{"doi-asserted-by":"crossref","unstructured":"66 Yamagishi M, Fujikawa D, Watanabe T, Uchimaru K. HTLV-1-Mediated Epigenetic Pathway to Adult T-Cell Leukemia-Lymphoma. Front Microbiol. 2018; 9: 1686.","key":"66","DOI":"10.3389\/fmicb.2018.01686"},{"doi-asserted-by":"crossref","unstructured":"67 Liang MH, Geisbert T, Yao Y, Hinrichs SH, Giam CZ. Human T-lymphotropic virus type 1 oncoprotein tax promotes S-phase entry but blocks mitosis. J Virol. 2002; 76: 4022-4033.","key":"67","DOI":"10.1128\/JVI.76.8.4022-4033.2002"},{"doi-asserted-by":"crossref","unstructured":"68 Sieburg M, Tripp A, Ma JW, Feuer G. Human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 tax oncoproteins modulate cell cycle progression and apoptosis. J Virol. 2004; 78: 10399-10409.","key":"68","DOI":"10.1128\/JVI.78.19.10399-10409.2004"},{"doi-asserted-by":"crossref","unstructured":"69 Sibon D, Gabet AS, Zandecki M <i>et al.<\/i> HTLV-1 propels untransformed CD4 lymphocytes into the cell cycle while protecting CD8 cells from death. J Clin Invest. 2006; 116: 974-983.","key":"69","DOI":"10.1172\/JCI27198"},{"doi-asserted-by":"crossref","unstructured":"70 Kinjo T, Ham-Terhune J, Peloponese JM Jr, Jeang KT. Induction of reactive oxygen species by human T-cell leukemia virus type 1 tax correlates with DNA damage and expression of cellular senescence marker. J Virol. 2010; 84: 5431-5437.","key":"70","DOI":"10.1128\/JVI.02460-09"},{"doi-asserted-by":"crossref","unstructured":"71 Cherian MA, Baydoun HH, Al-Saleem J <i>et al.<\/i> Akt Pathway Activation by Human T-cell Leukemia Virus Type 1 Tax Oncoprotein. J Biol Chem. 2015; 290: 26270-26281.","key":"71","DOI":"10.1074\/jbc.M115.684746"},{"doi-asserted-by":"crossref","unstructured":"72 El Hajj H, Bazarbachi A. Interplay between innate immunity and the viral oncoproteins Tax and HBZ in the pathogenesis and therapeutic response of HTLV-1 associated adult T cell leukemia. Front Immunol. 2022; 13: 957535.","key":"72","DOI":"10.3389\/fimmu.2022.957535"},{"doi-asserted-by":"crossref","unstructured":"73 Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018; 48: 434-452.","key":"73","DOI":"10.1016\/j.immuni.2018.03.014"},{"doi-asserted-by":"crossref","unstructured":"74 Kozako T, Yoshimitsu M, Fujiwara H <i>et al.<\/i> PD-1\/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia\/lymphoma patients. Leukemia. 2009; 23: 375-382.","key":"74","DOI":"10.1038\/leu.2008.272"},{"doi-asserted-by":"crossref","unstructured":"75 Kataoka K, Shiraishi Y, Takeda Y <i>et al.<\/i> Aberrant PD-L1 expression through 3\u2032-UTR disruption in multiple cancers. Nature. 2016; 534: 402-406.","key":"75","DOI":"10.1038\/nature18294"},{"doi-asserted-by":"crossref","unstructured":"76 Koon HB, Junghans RP. Anti-CD30 antibody-based therapy. Curr Opin Oncol. 2000; 12: 588-593.","key":"76","DOI":"10.1097\/00001622-200011000-00012"},{"doi-asserted-by":"crossref","unstructured":"77 Donato EM, Fern\u00e1ndez-Zarzoso M, Hueso JA, de la Rubia J. Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review. Onco Targets Ther. 2018; 11: 4583-4590.","key":"77","DOI":"10.2147\/OTT.S141053"},{"doi-asserted-by":"crossref","unstructured":"78 Straus DJ, Dlugosz-Danecka M, Connors JM <i>et al.<\/i> Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 2021; 8: e410-e421.","key":"78","DOI":"10.1016\/S2352-3026(21)00102-2"},{"doi-asserted-by":"crossref","unstructured":"79 Horwitz S, O\u2019Connor OA, Pro B <i>et al.<\/i> Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019; 393: 229-240.","key":"79","DOI":"10.1016\/S0140-6736(18)32984-2"},{"doi-asserted-by":"crossref","unstructured":"80 Veyri M, Spano JP, Le Bras F, Marcelin AG, Todesco E. CD30 as a therapeutic target in adult haematological malignancies: Where are we now? Br J Haematol. 2023; 201: 1033-1046.","key":"80","DOI":"10.1111\/bjh.18841"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/4\/65_25041\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T04:42:00Z","timestamp":1766810520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/4\/65_25041\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.25041","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"type":"print","value":"1346-4280"},{"type":"electronic","value":"1880-9952"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"25041"}}